Aurora Private Wealth Inc. Purchases New Holdings in Amgen Inc. (NASDAQ:AMGN)

Aurora Private Wealth Inc. acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 14,388 shares of the medical research company's stock, valued at approximately $4,483,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Pinney & Scofield Inc. bought a new stake in shares of Amgen during the fourth quarter worth $26,000. Ritter Daniher Financial Advisory LLC DE boosted its stake in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after purchasing an additional 51 shares during the period. Synergy Investment Management LLC bought a new stake in shares of Amgen in the fourth quarter valued at about $34,000. Atala Financial Inc bought a new stake in shares of Amgen in the fourth quarter valued at about $34,000. Finally, Heck Capital Advisors LLC bought a new position in shares of Amgen during the fourth quarter worth about $36,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on AMGN. Guggenheim assumed coverage on Amgen in a research note on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 target price on the stock. Wall Street Zen raised shares of Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. UBS Group reaffirmed a "neutral" rating and issued a $315.00 target price (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Piper Sandler lowered their price target on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a research note on Friday, May 16th. Finally, William Blair restated an "outperform" rating on shares of Amgen in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $309.22.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president now directly owns 8,162 shares of the company's stock, valued at $2,364,368.16. This represents a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.76% of the stock is currently owned by insiders.

Amgen Stock Performance

Shares of AMGN stock traded down $1.24 during midday trading on Thursday, hitting $279.11. 2,998,199 shares of the company were exchanged, compared to its average volume of 2,829,810. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The firm has a market capitalization of $150.08 billion, a P/E ratio of 25.47, a PEG ratio of 2.54 and a beta of 0.51. The firm's 50 day moving average price is $280.99 and its two-hundred day moving average price is $286.00. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The firm had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period last year, the business posted $3.96 earnings per share. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.